Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: Asssessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 1, 2007, Pages 346-355

  Kalvass, J Cory ^a,c   Olson, Emily R ^a   Cassidy, Michael P ^b   Selley, Dana E ^b   Pollack, Gary M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; FENTANYL; GLYCOPROTEIN P; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); LOPERAMIDE; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; OPIATE; PETHIDINE; SUFENTANIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALGESICS, OPIOID; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; DRUG EVALUATION, PRECLINICAL; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MALE; MICE; MODELS, BIOLOGICAL; P-GLYCOPROTEINS; PAIN; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, MU;

EID: 34548842800     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.119560     Document Type: Article

References (23)

1. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
2. Chen C and Pollack GM (1997) Blood-brain disposition and antinociceptive effects of -D-penicillamine2,5-enkephalin in the mouse. J Pharmacol Exp Ther 283:1151-1159.
3. Cox EH, Kerbusch T, Van der Graaf PH, and Danhof M (1998) Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the μ-opioid receptor. J Pharmacol Exp Ther 284:1095-1103.
4. Dagenais C, Graff CL, and Pollack GM (2004) Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67:269-276.
5. Danhof M, Mandema JW, Hoogerkamp A, and Mathot RA (1993) Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives. Eur J Drug Metab Pharmacokinet 18:41-47.
6. Glare PA and Walsh TD (1991) Clinical pharmacokinetics of morphine. Ther Drug Monit 13:1-23.
7. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, and Foley KM (1987) Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 41:392-401.
8. Ito K, Yajima N, Ohtani H, Yamada Y, Nakamura K, Sawada Y, and Iga T (1993) Prediction of the therapeutic dose for beta-stimulants based on preclinical data: application of oral dosage forms and aerosols to asthmatic patients. J Pharmacokinet Biopharm 21:133-144.
9. Kalvass JC and Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338.
10. Kalvass JC, Maurer TS, and Pollack GM (2007a) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35:660-666.
11. Kalvass JC, Olson ER, and Pollack GM (2007b) Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. Drug Metab Dispos 35:455-459.
12. Kurz A, Ikeda T, Sessler DI, Larson MD, Bjorksten AR, Dechert M, and Christensen R (1997) Meperidine decreases the shivering threshold twice as much as the vasoconstriction threshold. Anesthesiology 86:1046-1054.
13. 3H] Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord. Eur J Pharmacol 87:209-225.
14. Lötsch J (2005) Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 29:S90-S103.
15. Meuldermans WE, Hurkmans RM, and Heykants JJ (1982) Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn Ther 257:4-19.
16. Niemegeers CJ, McGuire JL, Heykants JJ, and Janssen PA (1979) Dissociation between opiate-like and antidiarrheal activities of antidiarrheal drugs. J Pharmacol Exp Ther 210:327-333.
17. Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524.
18. Selley DE, Cao CC, Liu Q, and Childers SR (2000) Effects of sodium on agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO cells and rat thalamus. Br J Pharmacol 130:987-996.
19. 35S]GTPγS binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther 285:496-505.
20. Selley DE, Sim LJ, Xiao R, Liu Q, and Childers SR (1997) μ-Opioid receptor-stimulated guanosine-5′-O-(γ-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol 51:87-96.
21. Terenius L (1975) Comparison between narcotic "receptors" in the guinea-pig ileum and the rat brain. Acta Pharmacol Toxicol (Copenh) 37:211-221.
22. Visser SA, Wolters FL, Gubbens-Stibbe JM, Tukker E, Van Der Graaf PH, Peletier LA, and Danhof M (2003) Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J Pharmacol Exp Ther 304:88-101.
23. Wood M and Alastair JJ (1990) Drugs and Anesthesia: Pharmacology for Anesthesiologist, Williams & Wilkins, Baltimore, MD.